TRIV-509

DRUG2 trials

Sponsors

Triveni Bio Inc., Triveni Bio

Conditions

Atopic DermatitisAtopic dermatitis

Phase 2

A Study Evaluating TRIV-509 in Atopic Dermatitis

Active, not recruitingNCT07167758

Triveni BioAtopic Dermatitis

Start: 2025-08-26End: 2027-06-01Updated: 2026-04-27

A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-509 in Adults with Moderate to Severe Atopic Dermatitis

RecruitingCTIS2025-522113-35-00

Triveni Bio Inc.Atopic dermatitis

Start: 2026-01-07Target: 54Updated: 2026-01-20